Acumen Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Acumen Pharmaceuticals, Inc. (ABOS) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-03-27
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $399.00K, a 4333.33% increase year-over-year.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $9.00K.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $399.00K, a 64.88% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $242.00K.
- Acumen Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $399.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $399.00K derived: sum of 2 quarters · filed 2025-03-27 | $399.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $9.00K derived: sum of 2 quarters · filed 2024-03-26 | $9.00K derived: sum of 3 quarters · filed 2024-03-26 | $242.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $233.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $233.00K 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $233.00K 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |